tiprankstipranks
IMV Inc. to present initial patient data from VITALIZE trial
The Fly

IMV Inc. to present initial patient data from VITALIZE trial

IMV Inc. announced initial patient data from the VITALIZE Phase 2B trial evaluating its lead DPX product, MVP-S, in combination with pembrolizumab in patients with relapsed, refractory Diffuse Large B Cell Lymphoma who received at least three previous lines of treatment. Detailed results will be presented in a podium presentation at the Immuno-Oncology 360 degrees conference to be held in New York City on February 7-10, 2023.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on IMV:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles